ArticleCancer discovery2021
A Role for SMARCB1 in Synovial Sarcomagenesis Reveals That SS18-SSX Induces Canonical BAF Destruction.
Open access · bronzeAbstract read
In one paragraph
Article in Cancer discovery, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.
0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed
3.1field-weighted citation impact, top 7% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
37 citing papers in PubMed, 54 citations in OpenAlex.
- BRD9 Degraders Unleash GBAF Chromatin Remodeling Activity in Synovial Sarcoma.Cancer research · 2026Article
- BCL7A's arginine anchor links nucleosome recognition to chromatin remodeling and diffuse large B-cell lymphoma tumor suppression.Protein & cell · 2026Article
- BAF complex-independent gene activation by SS18::SSX.bioRxiv : the preprint server for biology · 2026Article
- Development of synovial sarcoma organoids exhibiting ferroptosis resistance despite low malic enzyme 1 expression.Scientific reports · 2025Article
- Synovial sarcoma reprograms transcription by GBAF activation of polycomb targets and loss of CBAF enhancers.Nature communications · 2025Article
- Article
- The fibroblast epigenome underlies SS18::SSX-mediated transformation in synovial sarcoma.Nature communications · 2025Article
- Targeting SUMOylation promotes cBAF complex stabilization and disruption of the SS18::SSX transcriptome in synovial sarcoma.Nature communications · 2025Article
- Genetically Modified Mouse Models for Sarcoma Research: A Comprehensive Review.Current oncology reports · 2025Review
- Molecular and epigenetic oncogenesis in synovial sarcoma: implications for cancer biology, diagnosis and treatment.Oncogene · 2025Review
- Targeting developmental vulnerabilities in childhood sarcomas.Cancer metastasis reviews · 2025Review
- Review
- DNA demethylating agents suppress preclinical models of synovial sarcoma.The Journal of clinical investigation · 2025Article
- Somatic gene delivery faithfully recapitulates a molecular spectrum of high-risk sarcomas.Nature communications · 2025Article
- Pharmacologic degradation of WDR5 suppresses oncogenic activities of SS18::SSX and provides a therapeutic of synovial sarcoma.Science advances · 2025Article
- The SS18-SSX fusion oncoprotein: Friend and foe in targeted therapy for synovial sarcoma.Oncology research · 2025Review
- Efficacy of CBP/p300 Dual Inhibitors against Derepression of KREMEN2 in cBAF-Deficient Cancers.Cancer research communications · 2025Article
- SS18-SSX drives TYK2 expression to activate STAT3/Bcl2 axis, facilitating apoptosis evasion and advancing synovial sarcoma progression.Cell biology and toxicology · 2024Article
- Targeted protein degradation: advances in drug discovery and clinical practice.Signal transduction and targeted therapy · 2024Review
- Chromatin remodellers as therapeutic targets.Nature reviews. Drug discovery · 2024Review
Corrections and comments
- Commented on by
Authors and funding
16 authors at 3 institutions in 2 countries.
Jinxiu Li *Department of Orthopedics, University of Utah, Salt Lake City, Utah.ORCID 0000-0002-1446-1751
Timothy S Mulvihill *Department of Oncological Sciences, University of Utah, Salt Lake City, Utah.
Li LiDepartment of Orthopedics, University of Utah, Salt Lake City, Utah.ORCID 0000-0002-1446-1751
Jared J BarrottDepartment of Orthopedics, University of Utah, Salt Lake City, Utah.ORCID 0000-0001-6059-9009
Mary L NelsonDepartment of Orthopedics, University of Utah, Salt Lake City, Utah.ORCID 0000-0003-3958-718X
Lena WagnerHopp Children's Cancer Center (KiTZ), German Cancer Research Center (DFKZ), Heidelberg, Germany.
Ian C LockDepartment of Orthopedics, University of Utah, Salt Lake City, Utah.
Amir PoznerDepartment of Orthopedics, University of Utah, Salt Lake City, Utah.
Sydney Lynn LambertDepartment of Orthopedics, University of Utah, Salt Lake City, Utah.
Benjamin B OzenbergerDepartment of Orthopedics, University of Utah, Salt Lake City, Utah.
Michael B WardHuntsman Cancer Institute, University of Utah, Salt Lake City, Utah.
Allie H GrossmannHuntsman Cancer Institute, University of Utah, Salt Lake City, Utah.ORCID 0000-0002-7665-1403
Ting LiuHuntsman Cancer Institute, University of Utah, Salt Lake City, Utah.ORCID 0000-0002-0747-0908
Ana BanitoHopp Children's Cancer Center (KiTZ), German Cancer Research Center (DFKZ), Heidelberg, Germany.
Bradley R CairnsDepartment of Oncological Sciences, University of Utah, Salt Lake City, Utah. kevin.jones@hci.utah.edu brad.cairns@hci.utah.edu.ORCID 0000-0002-9864-8811
Kevin B JonesDepartment of Orthopedics, University of Utah, Salt Lake City, Utah. kevin.jones@hci.utah.edu brad.cairns@hci.utah.edu.ORCID 0000-0003-1531-2157
University of Utah · USGerman Cancer Research Center · DEHoward Hughes Medical Institute · US
Funding
UTAH REGIONAL CANCER CENTERP30CA042014 · NCI · UTAH STATE HIGHER EDUCATION SYSTEM--UNIVERSITY OF UTAH · PI Jared P Rutter · 1986 to 2026
$72.6MTargeting SS18-SSX biology in synovial sarcomagenesisU54CA231652 · NCI · UNIVERSITY OF UTAH · PI JONES, KEVIN BRUCE · 2018 to 2022
$12.0MEpigenetic Mechanisms Driving Synovial SarcomagenesisR01CA201396 · NCI · UNIVERSITY OF UTAH · PI CAIRNS, BRADLEY R., JONES, KEVIN BRUCE · 2017 to 2021
$1.7MDysregulation of BAF chromatin remodeling in cancerF30CA225163 · NCI · UNIVERSITY OF UTAH · PI MULVIHILL, TIMOTHY · 2018 to 2021
$168kNCI NIH HHS F30 CA225163NCI NIH HHS P30 CA042014NCI NIH HHS R01 CA201396NCI NIH HHS U54 CA231652
Abstract
Reduced protein levels of SMARCB1 (also known as BAF47, INI1, SNF5) have long been observed in synovial sarcoma. Here, we show that combined
Indexed as
AnimalsCell Line, TumorCell Transformation, NeoplasticDisease Models, AnimalFemaleHumansMaleMiceMice, Inbred C57BLMice, TransgenicOncogene Proteins, FusionSarcoma, SynovialSMARCB1 ProteinOncogene Proteins, FusionSMARCB1 ProteinSMARCB1 protein, humanSS18-SSX1 fusion protein
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.